当前位置: 首页 >> 检索结果
5009. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21.
Mortality statistics are fundamental to public health decision making. Mortality varies by time and location, and its measurement is affected by well known biases that have been exacerbated during the COVID-19 pandemic. This paper aims to estimate excess mortality from the COVID-19 pandemic in 191 countries and territories, and 252 subnational units for selected countries, from Jan 1, 2020, to Dec 31, 2021.
5015. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
作者: Lorcan P McGarvey.;Surinder S Birring.;Alyn H Morice.;Peter V Dicpinigaitis.;Ian D Pavord.;Jonathan Schelfhout.;Allison Martin Nguyen.;Qing Li.;Anjela Tzontcheva.;Beata Iskold.;Stuart A Green.;Carmen La Rosa.;David R Muccino.;Jaclyn A Smith.; .
来源: Lancet. 2022年399卷10328期909-923页
Gefapixant is an oral P2X3 receptor antagonist that has previously shown efficacy and safety in refractory chronic cough and unexplained chronic cough. We therefore aim to confirm the efficacy and safety of gefapixant in participants with refractory chronic cough and unexplained chronic cough.
|